Low-Abundant Cerebrospinal Fluid Proteome Alterations in Dementia with Lewy Bodies

Jana-Katharina Dieksa,∗, Joanna Gawinecka, Abdul R. Asifb, Daniela Vargas, Karin Gmitterovad, Jan-Hendrik Streichc, Hassan Dihazic, Uta Heinemann, and Inga Zerrc,∗

aDepartment of Neurology, Clinical Dementia Center, Medical Center Georg-August University, Göttingen, Germany
bDepartment of Clinical Chemistry, Medical Center Georg-August University, Göttingen, Germany
cDepartments of Nephrology and Rheumatology, Medical Center Georg-August University, Göttingen, Germany
dSecond Department of Neurology, Comenius University, Bratislava, Slovakia

Accepted 6 November 2012

Abstract. Dementia with Lewy bodies (DLB) is one of the most common neurodegenerative diseases and shares multiple clinical and neuropathological parallels with Alzheimer’s (AD) and Parkinson’s disease (PD). A variety of clinical signs are suggestive for the diagnosis, and imaging (123I-CIT SPECT) contributes substantially to the diagnosis. The study reported here was performed in search for a biomarker in the cerebrospinal fluid (CSF) of these patients. We applied 2D fluorescence difference gel electrophoresis and mass spectrometry to analyze the CSF proteome pattern of DLB patients after depleting twelve high-abundant proteins. The densitometric analysis of 2D gels showed the up- or down-regulation of 44 protein spots. Subsequently, 23 different proteins were identified. The majority is involved in acute phase and immune response. Many of these proteins were previously reported before as being associated with AD or PD, which strongly suggests a molecular cross-talk and may explain clinical and pathological overlap of these disease entities. Among the identified proteins are two highly upregulated proteins—inter alpha tryptase inhibitor heavy chain (ITIH4) and calcyntenin 1—that may have the potential to serve as molecular biomarkers specific for DLB. The identification of DLB-associated proteome changes will help to further understand pathological processes occurring in DLB and may provide future prospects to diagnostic and therapeutic options.

Keywords: Biomarker, cerebrospinal fluid, dementia with Lewy bodies, 2-D fluorescence difference gel electrophoresis

Supplementary data available online: http://dx.doi.org/10.3233/JAD-121810

INTRODUCTION

According to various medical and scientific sources, Alzheimer’s disease (AD) followed by dementia with Lewy bodies (DLB) and vascular dementia accounts for most cases of neurodegenerative dementia in the elderly [1]. Clinical diagnostic criteria have been established for all three disease entities [2–4]. Nevertheless, definite diagnosis requires the pathological examination of the brain. An antemortem non- or only minimal invasive test in easily accessible tissue or fluids like cerebrospinal fluid (CSF), blood, or urine is therefore urgently needed because the accurate and early diagnosis is important for both patients and caregivers as
disease progression, development of symptoms, and treatment options and necessities differ significantly between the various types of dementia.

The clinical consensus guidelines define DLB as a progressive neurodegenerative disorder which is characterized by a rapid cognitive decline with co-existence of one or more of the core symptoms fluctuating attention, recurrent visual hallucinations, and spontaneous features of parkinsonism (support the diagnosis of a probable DLB) [3]. Recently, advanced imaging techniques such as 18F-FDG PET were reported to contribute substantially to the differential diagnosis [5]. At the histological level, DLB is characterized by the presence of widespread Lewy bodies and Lewy neurites which contain abnormally nitrated, phosphorylated, and ubiquitinated α-synuclein aggregates [6]. The pathological process in the brain leads to proteome changes and, subsequently, CSF that is surrounding the diseased tissue may reflect these alterations and serve as an important instrument in clinical routine.

In this study, we analyzed the CSF proteome pattern specific for patients with DLB. Depletion of twelve high-abundant CSF proteins prior to applying 2D fluorescence difference gel electrophoresis (2D-DIGE) approach followed by mass spectrometry enabled us to determine DLB-specific pathological proteome changes in the low-abundant protein fraction, which otherwise would be out of the detection range of the chosen analytical method.

The densitometric analysis of 2D gels showed the up- or down-regulation of 44 protein spots and consecutively 23 different proteins could be identified. These proteins, of which the majority was involved in acute phase and immune response, were assigned to five functional groups. Interestingly, many of these differentially regulated proteins were previously found to be associated with AD or Parkinson’s disease (PD).

PATIENTS, MATERIAL AND METHODS

Patients

For 2D-DIGE analysis, four CSF samples of DLB cases and four age- and gender-matched non-demented controls were used, each group consisting of two female and two male individuals. According to the consensus criteria proposed by McKeith et al. [3], DLB cases were classified as clinical probable cases (mean age 72 ± 7 years) and diagnostic lumbar puncture was performed at 4.7 ± 2.3 months after onset of disease. Individuals of the control group (CON) had a mean age of 71 ± 7 years and did not show any sign of cognitive decline or disease affecting the CNS. For both, DLB and control group, CSF parameters were located in normal, physiological ranges and did not show any evidence of acute or chronic inflammation and intrathecal immune response. Moreover, none of the DLB or control patients was a heavy smoker or drug- or alcohol-addict. For DLB patients, CSF-protein concentration was 395 ± 94 mg/l, lactate 1.6 ± 0.2 mmol/l, QAlb × 10^3 7.1 ± 2.3, and cell number 2 ± 1/µl. For control patients, CSF-protein concentration was 336 ± 39 mg/l, lactate 1.9 ± 0.1 mmol/l, QAlb × 10^3 4.7 ± 0.2, and cell number 1 ± 1/µl.

To confirm differential expression of selected proteins by western blot, CSF samples from eight DLB-patients, eight patients with AD, eight patients with PD, and eight non-demented control patients (CON) were chosen. For DLB patients, CSF-protein concentration was 512 ± 98 mg/l, for AD patients CSF-protein concentration was 464 ± 159 mg/l, for PD patients CSF-protein concentration was 414 ± 174 mg/l, and for control patients CSF-protein concentration was 384 ± 108 mg/l. The diagnosis of AD and PD was determined according to the diagnostic criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) and the National Institute of Neurological Disorders and Stroke (NINDS), respectively.

The human studies were approved by the local ethic committee (ethics proposal 36/7/02) and by an informed consent from all persons available.

2D fluorescence difference gel electrophoresis (2D-DIGE)

Sample preparation

CSF-samples were acquired by lumbar puncture for diagnostic purposes and stored at −80 °C until analysis was performed. At first, 2–4 ml of CSF were subjected to depletion of twelve high-abundant proteins (albumin, IgG total, IgM, IgA, transferrin, Apo A-I, Apo A-II, α1-Acid glycoprotein, α2-microglobulin, α1-antitrypsin, haptoglobin, and fibrinogen) using ProteomeLab IgG-12 LC2 Proteome Partitioning Kit (Beckman Coulter). The procedure was performed according to manufacturer’s instruction. Using 10 kDa Amicon filters (Millipore), sample volumes were concentrated up to around 200 µl and finally protein concentration was measured using 2-D Quant Kit (Amersham Biosciences). For 1D and 2D western...
showed at least 2-fold change in abundance and when differentially regulated when its densitometric analyses using unpaired Student's t-test were statistically evaluated using Delta2D software (v. 3.4) (DECODON). Differences in spot abundance detected by densitometric and statistical analysis was performed using ImageJ (Image Processing and Data Analysis free software) and Sigmaplot (Exact Graphs and Data Analysis software, Systat), respectively. Proteins were considered as specifically regulated when p-value was lower than 0.05 in Kruskal-Wallis ANOVA with Tukey’s range test.

2D Western blotting
Of each native, non-depleted CSF sample 150 μl of proteins were precipitated overnight with acetone-methanol (8 : 1; vol vol) at −20°C and then centrifuged at 16000 × g for 15 min. The pellet was then manually excised from silver- or Coomassie-stained gels and subjected to in-gel digestion. The detailed protocol of this procedure is given by Ramljak et al. [7]. In-gel digested peptides were chromatographically separated (C18 pepMap100 nano Series analytical column, LC Packings) and analyzed by ESI-Q-TOF Ultima Global mass spectrometer (Micromass). Data acquisition was performed using the MassLynx (v. 4.0) software and further processed on Protein-Lynx-Global-Server (v 2.1.), (Micromass). The acquired data files were searched against MSDB and SwissProt databases through the Mascot search engine using a peptide mass and MSMS fragment mass tolerance of 0.5 Da. The search criteria were set with one missed cleavage by trypsin allowed and protein modifications set to methionine oxidation and carbamidomethylcysteine when appropriate.

Western blotting

1D Western blotting
60 μl of native, non-depleted CSF samples were separated on 12% SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% skimmed milk in phosphate buffer saline with 0.2% Triton X-100 (TBST) for 1 h at room temperature (RT). Subsequently, membranes were incubated overnight at 4°C with the following primary antibodies: Rabbit anti-contactin 1 (1 : 500, Abcam), rabbit anti-chromogranin A (1 : 1500, Abcam), or rabbit anti-transthyretin (1 : 40000, Abcam). Thereafter, membranes were washed with PBST and incubated for 1h at RT with corresponding horseradish peroxide-conjugated secondary antibodies: Human-adsorbed anti-rabbit (1 : 7500, Santa Cruz Biotechnology) or goat anti-rabbit (1 : 10000, Abcam). Immunoreactivity was detected after immersion of membranes into enhanced chemiluminescence (ECL) solution and exposition to ECL-Hyperfilm (Amersham Biosciences). Films were scanned, thereafter, densitometric analysis was performed using ImageJ (Image Processing and Data Analysis free software) and Sigmaplot (Exact Graphs and Data Analysis software, Systat), respectively. Proteins were considered as specifically regulated when p-value was lower than 0.05 in unpaired Student’s t test. A protein spot was considered as differentially regulated when its densitometric analyses showed at least 2-fold change in abundance and when p-value was <0.05 in unpaired Student’s t test.

Protein identification
Gel plugs containing the proteins of interest were manually excised from silver- or Coomassie-stained
resuspended in a lysis buffer and loaded on a Ready-Strip IPI pH 3–10, 7 cm strip (Bio-Rad). After 12 h of active rehydration at 50 V, isoelectric focusing was initiated at 200 V for 1 h, followed by ramping at 500 V for 1 h and 1000 V for 1.5 h. The final focusing was carried out at 8000 V reaching a total of 30000 Vh (PROTEAN IEF CELL, Bio-Rad). Subsequent steps were performed as described above.

RESULTS

General observations

Using Delta 2D's 100% spot matching approach, we detected a total amount of 1,978 protein spots on the 2D proteome patterns of the low-abundant protein fraction from CSF of DLB patients. Densitometric and statistical analysis revealed that 44 protein spots (2.2 % of all protein spots) showed differential expression in DLB (Fig. 1). Of these, 37 protein spots were identified by mass spectrometry, corresponding to 23 different proteins. Discrepancy between number of protein spots and proteins can be explained by the coexistence of different isoforms of the same proteins which vary in their isoelectric point and/or molecular weight. For the remaining seven protein spots, identification was not accomplishable due to very faint signal on silver- or colloidal Coomassie stained preparative gels. Moreover, protein spots 40 and 41 were identified as ITIH4 or calcytein 1; due to almost identical molecular weight and isoelectric point (pI), conclusive protein identification was not possible.

Of the 23 identified proteins, 20 were upregulated and two were down-regulated. Interestingly, for one protein one isoform showed an increased level while the second one showed a decreased level (Table 1).

Identified proteins were assigned to five different groups according to their biological functions using two independent sources for classification (IPA, Ingenuity Systems, trial version) web-based software application and UniProt protein database: Acute phase reactants (APRS)/immune response, glucose metabolism, lipid metabolism, cell structure and adhesion, and signal transduction (Fig. 2). Four proteins could not be allocated to these groups and were subsumed under “other function”. Major alteration in the low-abundant CSF proteome fraction of DLB patients
Table 1
List of DLB-related proteins in CSF. A protein spot was considered as DLB-regulated when its densitometric analyses showed at least 2-fold of change in abundance and when \( p \)-value was <0.05 in unpaired Student’s \( t \) test. # indicates two proteins, which due to very similar molecular weight, isoelectric point (pI), and Mascot score could not be ultimately differentiated from each other.

<table>
<thead>
<tr>
<th>D</th>
<th>Protein name</th>
<th>Fold of change</th>
<th>( p )-value</th>
<th>UniProt MW (kDa)</th>
<th>pI</th>
<th>Score</th>
<th>Queries matched</th>
</tr>
</thead>
<tbody>
<tr>
<td>40a</td>
<td>Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4)  #</td>
<td>87,9 ↑ 0.025</td>
<td>Q14624 103</td>
<td>6,5 580</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40b</td>
<td>Calsyntenin 1 (CSTN1)  #</td>
<td>87,9 ↑ 0.025</td>
<td>P094985 110</td>
<td>4,8 328</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41a</td>
<td>Complement C4a (CO4a)</td>
<td>6,6 ↑ 0.034</td>
<td>P04024 193</td>
<td>6,7 867</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41b</td>
<td>Complement C3 (CO3)</td>
<td>6,1 ↑ 0.042</td>
<td>P01024 187</td>
<td>6 428</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Chromogranin A (CGA)</td>
<td>4,9 ↑ 0.059</td>
<td>P01645 51</td>
<td>4,6 171</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Complement C3 (CO3)</td>
<td>3,4 ↑ 0.028</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Complement C3 (CO3)</td>
<td>3,1 ↑ 0.026</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Complement C3 (CO3)</td>
<td>3 ↑ 0.018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Complement C3 (CO3)</td>
<td>3,6 ↑ 0.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>D-isomerase (PDGDS)</td>
<td>2,5 ↑ 0.020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>D-isomerase (PDGDS)</td>
<td>2,2 ↑ 0.068</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>D-isomerase (PDGDS)</td>
<td>2,1 ↑ 0.029</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Glutathione peroxidase 3 (GPX3)</td>
<td>4,4 ↑ 0.027</td>
<td>P22332 26</td>
<td>8,3 112</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Prothrombin (THRB)</td>
<td>4,1 ↑ 0.027</td>
<td>P00734 70</td>
<td>5,6 643</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Contactin 1 (CNTN1)</td>
<td>3,6 ↑ 0.002</td>
<td>Q12460 113</td>
<td>5,6 179</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Transthyretin (TTHY)</td>
<td>3,3 ↑ 0.012</td>
<td>P00766 16</td>
<td>5,5 498</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Apolipoprotein A-IV precursor (APOA4)</td>
<td>3 ↑ 0.017</td>
<td>P06727 45</td>
<td>5,3 53</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Fructose-bisphosphate aldolase C (ALDOC)</td>
<td>2,7 ↑ 0.043</td>
<td>P09972 39</td>
<td>6,4 60</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Insulin-like growth factor-binding protein 2 (IGBP2)</td>
<td>2,5 ↑ 0.041</td>
<td>P18065 35</td>
<td>7,5 732</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Amyloid-like protein 1 (APLP1)</td>
<td>2,4 ↑ 0.005</td>
<td>P16093 72</td>
<td>5,5 301</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Pannexin-like proteins (PNNX)</td>
<td>2,2 ↑ 0.047</td>
<td>P14618 58</td>
<td>5,8 556</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Ganglioside GM2 activator (SAP5)</td>
<td>2,1 ↑ 0.025</td>
<td>P17900 21</td>
<td>5,2 69</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Ganglioside GM2 activator (SAP5)</td>
<td>2 ↑ 0.001</td>
<td>P16855 47</td>
<td>6,8 464</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>N-acetyllactosamine beta-1,3-N-acetyllactosaminyl-transf erase (B3GN1)</td>
<td>2 ↑ 0.039</td>
<td>Q43505 47</td>
<td>6,8 182</td>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

was observed in proteins involved in APRS/immune response.

Proteins involved in APRS/immune response
15 protein spots on 2D map corresponding to different isoforms of eight proteins were involved in APRS/immune response. Most of them act as direct or indirect activators of the complement system. Among them, complement C3, complement C4a, transthyretin, pigment epithelium-derived factor, and prothrombin were 2- to 7-fold upregulated, while ITIH4 showed the highest 60- to 88-fold upregulation. In contrast, angiotensinogen and albumin were around 2-fold down-regulated.
Fig. 2. The biological functions of DLB-associated proteins in CSF. The major alteration in CSF proteome was observed within the group of proteins involved in immune response. The remaining proteins were attributed to the following functional groups: glucose metabolism, lipid metabolism, signal transduction, and cell structure. Proteins that did not relate to any of those groups were subsumed in the group "others." *indicates two proteins, which due to very similar molecular weight, pl, and Mascot score could not be ultimately differentiated from each other.

Proteins associated with glucose metabolism
Three enzymes (fructose-bisphosphate aldolase C, pyruvate kinase isozymes M1/M2, and α-enolase) catalyzing important metabolic processes were 2- to 3-fold upregulated.

Proteins involved in lipid metabolism
Similarly, all three proteins involved in lipid metabolism displayed elevated levels in DLB. Four isoforms of prostaglandin-H2 D-isomerase were 2- to 5-fold upregulated. Two isoforms of ganglioside GM2 activator and apolipoprotein A-IV showed 2- and 3-fold upregulation, respectively.

Proteins involved in cell structure and adhesion
Contactin 1 and gelsolin, both associated with cell adhesion and cytoskeleton, were significantly 2- to 5-fold upregulated. Calsyntenin 1 shared the highest 60- to 88-fold upregulation with ITIH4.

Proteins involved in signal transduction
Chromogranin A isoforms displayed 2- to 5-fold increase in concentration while insulin-like growth factor-binding protein 2 showed 2.5-fold upregulation.

Other differentially regulated proteins in DLB
The remaining proteins (amyloid-like protein 1, N-acetyllactosamine beta-1,3-N-acetylglucosaminyltransferase (B3GN1), glutathione peroxidase 3, and cystatin C) were not classified as belonging to one of the above mentioned functional groups. Amyloid-like protein 1 and B3GN1 were around 2-fold upregulated while glutathione peroxidase 3 more than 4-fold. Cystatin C, an important inhibitor of cysteine proteinases, was corresponding to two oppositely regulated protein spots (ID 19: 2.6-fold upregulated, ID 20: 3.8-fold down-regulated) with slightly different molecular weight. It is likely that in DLB cystatin C either undergoes some modification resulting in the observed molecular weight shift or that the two isoforms are modulated in an opposite manner.

Verification of 2D-DIGE experiments
Further, we focused our interest on three particular proteins belonging to different functional groups and performed 2D and 1D western blot analysis in order to validate our findings from 2D-DIGE experiments. Analysis was performed for transthyretin, contactin 1, and chromogranin A. Representative 2D western blots were performed in order to reinforce 2D-DIGE results and to support following 1D western blot analysis (Fig. 3). Using 1D immunoblots, protein levels in CSF were compared between DLB, AD, and PD patients as well as non-demented control patients. Each group consisted of eight individuals (Fig. 4).

Transthyretin immunoblot analysis revealed the presence of two bands corresponding to transthyretin dimers and monomers. The monomeric form was 1.6-fold upregulated in DLB in comparison to CON. No further significant change in protein abundance was detected for neither monomers nor dimers. Interestingly, dimer western blot map showed a double band...
in three out of eight PD patients but in no other group (Fig. 4A).

A significant increase in contactin 1 level was found in DLB compared to all other groups. The highest 3.4-fold of change was computed between DLB and PD while the lowest 2-fold of change was between DLB and AD. Finally, almost 3-fold of change was found between DLB and CON (Fig. 4B).

Furthermore, two bands were analyzed from chromogranin A immunoblot. The upper band at around 45 kDa corresponds to the native chromogranin A molecule and the lower one at 20 kDa is possibly a truncated form. No significant difference between DLB and CON was detected either for the upper or for the lower band of chromogranin A. However, two chromogranin A forms were 2- to 3-fold upregulated in PD in comparison to DLB. The native form was also 2.6-fold upregulated in AD compared to DLB (Fig. 4C).

DISCUSSION

DLB is a progressive and disabling neurodegenerative disease, the second most common after AD [8]. Due to the overlap of clinical signs and symptoms with AD or PD, DLB is often diagnosed late or even misdiagnosed [9].

At histological level, DLB is characterized by the presence of Lewy bodies and Lewy neurites mainly formed of abnormally modified and aggregated $\alpha$-synuclein as a part of a complex pathology leading to proteome changes in the CNS tissue [3, 6]. Subsequently, CSF as the unique body fluid surrounding the diseased brain may reflect these alterations. Yet in our study, proteins characteristic for common features of the DLB pathology such as $\alpha$-synuclein, and other components of Lewy bodies such as crystalline, ubiquitin, and enzymes of the ubiquitin cycle, tau, amyloid-\beta, or synaptophysin were not found to be specifically regulated in CSF. Rather we found various CSF proteins to be regulated that are known to be involved in biological functions known to be related to a multitude of neurodegenerative processes. Although overlap is usually high, proteins found to be important in the diseased brain tissue must not necessarily be found in CSF.

However, CSF analysis is challenging in terms of a high dynamic range of protein concentrations. Particular proteins such as albumin or immunoglobulins are dominant in CSF and conceal many low-abundant proteins so these remain undetected when analyzed by conventional techniques such as 2D gel electrophoresis and mass spectrometry. Therefore, to achieve a more effective coverage of low-abundance proteins, the immunodepletion of twelve of the highest-abundant CSF proteins was performed. Nevertheless, albumin, which belongs to the twelve proteins undergoing depletion, was found as down-regulated in DLB. According to manufacturer’s instructions, the partitioning efficiency of the used kit differs for the various depleted proteins from 90 to >99.5%. Albumin is the most
Fig. 4. Relative levels of transthyretin, contactin 1, and chromogranin A. The DLB-related regulation of transthyretin (A), contactin 1 (B), and chromogranin A (C) was analyzed in a larger group of DLB, CON, AD, and PD patients. In brief, the monomeric form of transthyretin was 1.6-fold upregulated in DLB compared to CON, but no further significant change in protein abundance was detected, neither for monomers nor for dimers. A significant 2- to 3-fold increase in contactin 1-level was found in DLB in comparison to all other groups. No significant difference between DLB and CON was detected, neither for the upper nor for the lower band of chromogranin A. However, two chromogranin A forms were upregulated in PD compared to DLB. The native form was also upregulated in AD in comparison to DLB. The representative blots are shown below graphs. *p < 0.05 in Kruskal–Wallis ANOVA test.
abundant protein in human CSF and its upper normal range in adults is 0.5 mg/ml. Therefore, its concentration even after depletion was still sufficient to detect it on 2D CyDye-labeled gels (detection limit is around 0.25 ng of protein). The densitometric and statistical analysis of CSF 2D maps revealed the differential expression of 23 distinct proteins. Western blot analysis of three proteins (transferrin, contactin 1, and chromogranin A) was performed and mostly confirmed our findings on 2D maps. Contactin 1 even showed a promising significant differentiation not only between DLB and healthy control patients but also AD and PD which might be helpful in terms of diagnostic potential. Results for regulation of chromogranin A obtained by 2D gels could not be confirmed in classic western blot analysis. One possible explanation for this may be the different technical properties of 2D gel electrophoresis versus western blot analysis. Also, CSF was subjected to depletion of twelve high-abundant proteins prior to applying 2D gel electrophoresis. For western blots, native CSF samples were used. Therefore interferences of high-abundant proteins are possible.

Neuroinflammation is a critical component in progression of many neurodegenerative diseases, including DLB, as has been demonstrated. It has been previously shown that aggregated α-synuclein activates microglia and astrocytes inducing neuroinflammatory response [10]. Another immunochemical study revealed classical complement pathway activators like C3 and C4 in degenerating Lewy body-bearing neurons and extracellular Lewy bodies as potential inductors of immune response and microglial activation [11]. Complement activation also occurs around Lewy bodies and melanized neurons in the substantia nigra of PD-affected brain [12]. Moreover, expression levels of acute phase proteins are strongly regulated by inflammatory mediators. Taken together, these data are in accordance with our findings on major alteration in inflammatory mediators. Many proteins differentially regulated in DLB identified in this study have been found to be regulated in CSF of AD or PD patients. The most frequent reported proteins in both diseases are chromogranin A, cystatin C, prostaglandin-H2 D-isomerase, pigment epithelium-derived factor, and gelsolin [21–24]. These common molecular mechanisms might be reflected in overlapping proteomic changes in the CSF making conclusive differential diagnosis using a biomarker a challenging task. Many proteins become a CSF biomarker for DLB as the fact that one misfolding protein can promote accumulation of another one, may be the key component to linking the pathologies of AD, PD, and DLB [19, 20]. These common molecular mechanisms might be reflected in overlapping proteomic changes in the CSF making conclusive differential diagnosis using a biomarker a challenging task. Many proteins become a CSF biomarker for DLB identified in this study have been found to be regulated in CSF of AD or PD patients. The most frequent reported proteins in both diseases are chromogranin A, cystatin C, prostaglandin-H2 D-isomerase, pigment epithelium-derived factor, and gelsolin [21–24].

In our study, ITIH4 and calsyntenin 1 were identified as the highest regulated in DLB. The potential for both proteins becomes a CSF biomarker for DLB requires further technical development toward an easy applicable and widely available detection system. Interestingly, among various other proteins ITIH4 was already proposed a candidate CSF biomarker that may reflect AD-related pathophysiology [22]. In the same proteomic study, calsyntenin 1 was also reported to be down-regulated in CSF of AD patients [22]; in contrast calsyntenin 1 was found to be upregulated in CSF of PD patients [24]. Further analysis of both these proteins in CSF of all disease entities analyzed in this study seems adequate and promising of relevant findings.
In summary, depletion of twelve high abundant proteins enabled us to have deeper insight in DLB-associated proteome changes in CSF. The identification of DLB-associated protein changes will help to further understand pathological processes occurring in DLB and may provide future prospects to diagnostic and therapeutic options. Novel CSF biomarkers highly specific for DLB would be substantial when facing difficulties in distinguishing between DLB from AD and PD, which show multiple parallels in clinicopathological presentation.

SUPPORTING INFORMATION

One supplementary file (available online: http://www.j-alz.com/suppldata03) contains MS data including MS/MS spectra for proteins identified from 3 or less peptides.

ACKNOWLEDGMENTS

This study is supported by grants from Bundesministerium für Bildung und Forschung within the German Network for Degenerative Dementia (KNDD-2, 2012-2015), determinants for disease progression in AD, grant No. 01GI1010C), within the framework of the Joint Programme Neurodegenerative Disease research - JPND - Biomarker based diagnosis in rapid progressive dementia, 01ED1201A and Verein zur Förderung Alzheimer’s disease, 01ED1201A and Verein zur Förderung der Forschung an der Neurologischen Klinik e.V. Authors thank Barbara Ciesielczyk, Christa Scholz, and Christina Wiese for their outstanding technical help and valuable advice.


REFERENCES


